[The efficacy and safety of teraligen in patients with brain ischemia, stages I and II, and psychoautonomic syndrome].

Objective: To assess the efficacy and safety of teraligen in patients with psychoautonomic syndrome comorbid to brain ischemia.

Material And Methods: Forty-five patients, aged from 42 to 65 years (mean age 56 years), diagnosed with brain ischemia, stages I and II, with the signs of psychoautonomic syndrome were examined. Thirty-five patients received teraligen in the daily dose of 15 mg.